Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck finishes alcohol dependency trials

Lundbeck completes phase III trials for alcohol dependency drug nalmefene

Lundbeck has completed the final study in its phase III programme to evaluate nalmefene for the treatment of alcohol dependence.

Unlike existing therapies, treatment with nalmefene is not aimed at keeping patients from drinking, but instead it helps patients control and limit their intake of alcohol. In addition, nalmefene is available as a tablet to be taken when required, whereas existing drugs must be taken continuously over a longer period of time and are aimed at maintaining abstinence.

Lundbeck assessed a wide range of primary and secondary endpoints in its phase III programme, including: number of heavy drinking days per month, total alcohol consumption; proportion of responders based on drinking measures, alcohol dependence symptoms and clinical status, liver function and other laboratory tests, pharmaco-economic outcomes and treatment discontinuation effects. All assessments were consistently in favour of nalmefene compared to placebo, though some were not statistically significant at every single milestone.

Overall, nalmefene reduced heavy drinking days and total alcohol consumption by more than 50 per cent compared to pre-treatment baseline. The effect was observed during the first month of treatment and was maintained throughout the study period in the three trials.

The most frequent side effects reported by patients were dizziness, insomnia and nausea. These were usually mild and transient in nature.

Lundbeck plans to file a marketing authorisation application (MAA) in Europe by the end of 2011.

15th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics